KA-3001

N/A

Report date: 2026/03/19 17:15:08

Base Information

Drug NameKA-3001

Drug Alias NameKA-3001

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-PSMAAnti-CD28

TargetsProstate-Specific Membrane AntigenT-cell-specific surface glycoprotein CD28

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKYinno Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesKYinno Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A